Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare disease. Although much progress has been made in the understanding of the pathophysiology of the disease, far less is known with respect to the clinical outcomes of patients with PNH. Few retrospective studies provide survival estimates, and even fewer have explored the clinical heterogeneity of the disease. Haemolytic and aplastic anaemia (AA) forms of the disease have been recognised as main disease categories, with the haemolytic form being associated with the worst prognosis by the largest studied cohort some years ago.

[1]  M. Gladwin,et al.  Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria , 2010, British journal of haematology.

[2]  W. Gregory,et al.  Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. , 2010, Blood.

[3]  R. Storb,et al.  Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. , 1976, Blood.

[4]  N. Young,et al.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. , 2008, Blood.

[5]  W. Rosse,et al.  The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. , 1996, Blood.

[6]  E. S. Garrett,et al.  Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays , 2004, British journal of haematology.

[7]  N. Young,et al.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.

[8]  J. Maciejewski,et al.  Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry , 2014, Haematologica.

[9]  J. Mary,et al.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors , 1996, The Lancet.

[10]  S. Lewis,et al.  Paroxysmal Nocturnal Haemoglobinuria: Variation in Clinical Severity and Association with Bone‐Marrow Hypoplasia , 1961, British journal of haematology.

[11]  W. Rosse Dr Ham's test revisited [editorial] , 1991 .

[12]  W. Rosse,et al.  Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. , 1989, The Journal of clinical investigation.

[13]  Teizo Fujita,et al.  Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria , 1993, Cell.

[14]  N. Young,et al.  Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. , 2007, Blood.

[15]  W. Dameshek Riddle: what do aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH) and "hypoplastic" leukemia have in common? , 1967, Blood.

[16]  Neal Young,et al.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.

[17]  Sung-Soo Yoon,et al.  Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry , 2013, International Journal of Hematology.

[18]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[19]  S. Richards,et al.  Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). , 2003, Blood.

[20]  W. Rosse,et al.  The natural history of paroxysmal nocturnal hemoglobinuria. , 1997, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[21]  S. Hall,et al.  Clinical Course and Flow Cytometric Analysis of Paroxysmal Nocturnal Hemoglobinuria in the United States and Japan , 2004, Medicine.

[22]  M. Mohty,et al.  Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. , 2008, Blood.

[23]  R. Brodsky,et al.  Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia , 2010, European journal of haematology.

[24]  N. Young,et al.  The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. , 2009, Seminars in hematology.

[25]  S. Lewis,et al.  Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease. , 1972, Series haematologica.

[26]  Pierre-Yves Dumas,et al.  Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study , 2016, American journal of hematology.

[27]  D. Blaise,et al.  Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria , 2012, Haematologica.

[28]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .